May Health is pioneering a novel treatment approach for Polycystic Ovary Syndrome (PCOS) through its Ovarian Rebalancing™ procedure. This innovative treatment focuses on targeted ovarian ablation, which aims to lower androgen production and restore ovulation without the need for hormonal therapies. The procedure is designed to be performed conveniently in a physician's office, emphasizing accessibility for patients. Currently, May Health is in the clinical trial phase, adhering to FDA and EU regulations to ensure the safety and effectiveness of this investigational device, with a particular focus on addressing PCOS-related infertility.

The May Health System, utilized in the Ovarian Rebalancing™ procedure, is still under investigation, and no definitive claims regarding its safety or effectiveness have been established at this stage. Preliminary studies, such as the ULTRA trials, suggest that the device may effectively restore ovulation in women with PCOS who have not responded to first-line oral medications. However, further multicenter studies are necessary to validate these findings and assess the long-term effects and metabolic implications of the treatment. May Health is committed to providing objective information to both patients and healthcare professionals as they navigate the complexities of PCOS management.

France

May Health is a healthcare company that is developing a modern approach to PCOS.

May Health

Company Details